Kato Hiroyuki, Usui Masanobu, Azumi Yoshinori, Ohsawa Ichiro, Kishiwada Masashi, Sakurai Hiroyuki, Tabata Masami, Isaji Shuji
Department of Hepatobiliary Pancreatic Surgery, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan.
World J Gastroenterol. 2008 Jul 14;14(26):4245-8. doi: 10.3748/wjg.14.4245.
Although interferon (IFN) based therapy for recurrent hepatitis C virus (HCV) infection after liver transplantation has been widely accepted, it induces various adverse effects such as thrombocytopenia, resulting in its interruption. Recently, concomitant splenectomy at the time of living donor liver transplantation (LDLT) has been tried to overcome this problem, but this procedure leads to several complications such as excessive intraoperative bleeding and serious infection. A 60-year-old female received LDLT using a left lobe graft from her second son for liver failure caused by hepatitis C-related cirrhosis. Six months after LDLT, she was diagnosed as recurrent HCV infection by liver biopsy. IFN monotherapy was started from 7 mo after LDLT and her platelet count decreased to less than 50,000/microL, which thus made it necessary to discontinue the treatment. We decided to attempt laparoscopic splenectomy (LS) under general anesthesia. Since intra-abdominal findings did not show any adhesion formations around the spleen, LS could be successfully performed. After LS, since her platelet count immediately increased to 225,000/microL 14 d after operation, IFN therapy was restarted and we could convert the combination therapy of IFN and ribavirin, resulting in no detectable viral marker. In conclusion, LS can be performed safely even after LDLT, and LS after LDLT is a feasible and less invasive modality for thrombocytopenia caused by antiviral therapy.
尽管基于干扰素(IFN)的疗法用于肝移植后复发性丙型肝炎病毒(HCV)感染已被广泛接受,但它会引发各种不良反应,如血小板减少,导致治疗中断。最近,有人尝试在活体肝移植(LDLT)时同时进行脾切除术来克服这一问题,但该手术会导致一些并发症,如术中出血过多和严重感染。一名60岁女性因丙型肝炎相关肝硬化导致肝衰竭,接受了来自其二儿子左叶移植物的LDLT。LDLT后6个月,经肝活检诊断为复发性HCV感染。IFN单药治疗于LDLT后7个月开始,她的血小板计数降至低于50,000/微升,因此有必要停止治疗。我们决定在全身麻醉下尝试腹腔镜脾切除术(LS)。由于腹腔内检查未发现脾脏周围有任何粘连形成,LS得以成功实施。LS后,由于她的血小板计数在术后14天立即升至225,000/微升,IFN治疗重新开始,我们能够将IFN与利巴韦林的联合治疗转变为单一治疗,结果病毒标志物检测不到。总之,即使在LDLT后也可安全地进行LS,LDLT后的LS对于抗病毒治疗引起的血小板减少是一种可行且侵入性较小的治疗方式。